Sec Form 4 Filing - TLS Beta Pte. Ltd. @ Guardant Health, Inc. - 2018-10-09

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person TLS Beta Pte. Ltd. 2. Issuer Name and Ticker or Trading Symbol Guardant Health, Inc. [ GH] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 60B ORCHARD ROAD #06-18, TOWER 2 THE ATRIUM@ORCHARD 3. Date of Earliest Transaction (MM/DD/YY) 10/09/2018 (Street) SINGAPORE, U0238891 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price COMMON STOCK 10/09/2018 C 1,016,995 A 1,016,995 I ( 2 ) By TLS Beta Pte. Ltd. ( 2 ) COMMON STOCK 10/09/2018 C 596,012 A 596,012 I ( 2 ) By TLS Beta Pte. Ltd. ( 2 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares SERIES D PREFERRED STOCK ( 1 ) 10/09/2018 C 1,016,995 ( 1 ) ( 1 ) COMMON STOCK 1,016,995 ( 1 ) 0 I ( 2 ) By TLS Beta Pte. Ltd. ( 2 ) SERIES E PREFERRED STOCK ( 1 ) 10/09/2018 C 596,012 ( 1 ) ( 1 ) COMMON STOCK 596,012 ( 1 ) 0 I ( 2 ) By TLS Beta Pte. Ltd. ( 2 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other TLS Beta Pte. Ltd. 60B ORCHARD ROAD #06-18 TOWER 2 THE ATRIUM@ORCHARD SINGAPORE, U0238891 X Temasek Life Sciences Private Ltd 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE238891 X Fullerton Management Pte Ltd 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE238891 X Temasek Holdings (Private) Ltd 60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD SINGAPORE238891 X Signatures TLS Beta Pte Ltd., /s/Christina Choo Soo Shen, Director 10/11/2018 Signature of Reporting Person Date Temasek life Sciences Private Limited, /s/Lim Siew Lee Sherlyn, Director 10/11/2018 Signature of Reporting Person Date Fullerton Management Pte. Ltd., /s/Cheong Kok Tim, Director 10/11/2018 Signature of Reporting Person Date Temasek Holdings (Private) Limited, /s/Christina Choo Soo Shen, Authorized signatory 10/11/2018 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. ( 2 )The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.